About Amgen
Amgen is a publicly listed company based in Thousand Oaks (United States) founded in 1980. Developer of pharmaceutical products for treating multiple diseases. The company has 28,000 employees. Amgen has completed 26 acquisitions, including Abgenix, Alantos Pharmaceuticals and Amgen Astellas BioPharma. Its chief executive, as recorded, is Robert Bradway. Its website amgen.com draws about 495 thousand monthly visits. Its Indian entity Amgen Technology Private Limited reported revenue of ₹166 Cr. Amgen offers products and services including Biologic Medicines and Clinical Trials Services. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.
Company details
Amgen was founded in 1980 in Thousand Oaks, United States, within the biotechnology sector. Pharmaceutical products are developed to address multiple diseases through advances in cellular and molecular biology. Human therapeutics are manufactured and marketed, with operations centered on hematology, oncology, and inflammation. In 2022, annual revenues of 26.32 billion were achieved, alongside a net profit of 6.55 billion.
- Indian entity revenue₹166 Cr
FY 2025 · +601% YoY
- Indian entity net profit₹12.46 Cr
FY 2025 · 7% margin
- Indian entity EBITDA₹29.68 Cr
FY 2025 · 18% margin
- Latest Funding Round$175.46M (USD), Post-IPO
Mar 2012
- Investors
- Employee Count28,000
- Investments & AcquisitionsAbgenix
& 25 more
Associated legal entities of Amgen
Amgen operates through Amgen Technology Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Amgen Technology Private Limited CIN U62099MH2007FTC168485 | Active | 08 Mar 2007 | Mumbai, Maharashtra | ₹166 Cr | 22 | 5 | View details |
Products & Services of Amgen
Amgen offers a comprehensive portfolio of products and services, including Biologic Medicines and Clinical Trials Services.
Treatments for serious illnesses through biologic innovations.
Platforms for optimizing and conducting medical trials worldwide.
Apps and channels of Amgen
Amgen publishes 1 mobile app with over 5K+ downloads; its YouTube channel Amgen has 928 subscribers and 30 videos.
Videos from Amgen
The most watched videos on Amgen's YouTube channel, Amgen (928 subscribers). Click a video to play it here.
More on Amgen.
Funding Insights of Amgen
- Total Rounds 2
- Last Round Post-IPO — $175.46M
- Investors Count 1
All 2 funding rounds of Amgen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2012 | $175.46M | Post-IPO | – | – | – |
| Jan 2010 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Amgen
Amgen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Amgen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Amgen Technology Private Limited (Amgen)
Amgen Technology Private Limited is the primary company behind Amgen. The board of Amgen Technology Private Limited currently have 5 directors; the longest-serving is Ng Lian Eric Teck, appointed in 2017. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ng Lian Eric Teck DIN 07910958 | Director | 31 Aug 2017 | 9 yrs 2 mo | Amgen Technology Private Limited |
| Mansi Jayantilal Malkan DIN 07936492 | Director | 15 Sep 2017 | 9 yrs 1 mo | Amgen Technology Private Limited |
| David Ewan Foulstone DIN 10545698 | Director | 20 Mar 2024 | 2 yrs 7 mo | Amgen Technology Private Limited |
| Naveen Gullapalli DIN 06889417 | Whole-time director | 23 Apr 2025 | 1 yr 6 mo | Amgen Technology Private Limited |
| Mihir Kumar Ojha DIN 11100517 | Whole-time director | 09 May 2025 | 1 yr 5 mo | Amgen Technology Private Limited |
People of Amgen
1109 people are tracked at Amgen (432 in leadership, 47 in board & advisors, 630 in team); the tracked headcount is 28,000.
| Name | Role | Group |
|---|---|---|
Robert Bradway | CEO & Chairman | Leadership |
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
Tara U. | Director, Global Corporate Affairs, Operations | Leadership |
1089 more people are available in the full profile.
Complete people profiles for Amgen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Amgen
Amgen is a publicly listed company on the NASDAQ with ticker symbol AMGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Jun 2012
- Listed onBMV: AMGN
- Listed entityAmgen Inc.
- Exchange sectorHealth technology
- ISINUS0311621009
- Share price$412.84 (-1.13% on the day) · 2026-10-13
- Market capitalisation$223.19B
- Price to earnings25.6
- EPS (diluted, trailing year)$16.10
- Dividend yield2.41%
- Volume (last session)2,319,612
Financials of Amgen
Figures of Amgen Technology Private Limited, the primary company behind Amgen, for FY 2025. Revenue was ₹166 Cr (+601% year on year). Net profit was ₹12.46 Cr (7% margin). EBITDA was ₹29.68 Cr (18% margin). Revenue has grown at a compounded annual rate of +79% over three years and +42% over five years.
- ₹166 CrRevenue · FY 2025 · +601% YoY
- ₹12.46 CrNet profit · 7% margin
- ₹29.68 CrEBITDA · 18% margin
- ₹1 LakhPaid-up capital
- 22Employees (provident fund records)
- +79%Revenue CAGR, 3 years
- +42%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $36.74B | $7.71B | $15.84B |
| 2024 | $33.23B | $4.09B | $13.90B |
| 2023 | $28.01B | $6.72B | $13.06B |
| 2022 | $26.09B | $6.55B | $12.60B |
| 2021 | $25.99B | $5.89B | $12.55B |
Balance sheet, profit and loss, cash flow and ratios of Amgen Technology Private Limited are on its company page.
Detailed financial statements for Amgen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amgen
Amgen has strategically engaged in corporate development activities, having acquired 26 companies. Notable acquisitions include Abgenix, Alantos Pharmaceuticals and Amgen Astellas BioPharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops precision medicines for cancer using expert partnerships and drug pipelines. | darkbluetx.com | Oxford, United Kingdom | 2020 | Jan 2026 | •••• | |
Developer of drugs for treating rare and autoimmune diseases | horizontherapeutics.com | Dublin, Ireland | 2008 | Dec 2022 | $27.8B | |
Orphan drugs for autoimmune, inflammatory, and rare diseases are developed. | chemocentryx.com | Mountain View, United States | 1997 | Aug 2022 | $4B | |
Developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases | teneobio.com | Menlo Park, United States | 2007 | Jul 2021 | $900M | |
Prostaglandin-degrading enzyme inhibitors are developed for inflammatory bowel disease treatment. | rodeotherapeutics.com | Seattle, United States | 2017 | Mar 2021 | $55M | |
Antibodies for cancer and inflammatory diseases treatment are developed. | fiveprime.com | San Francisco, United States | 2002 | Mar 2021 | $1.9B | |
Amgen's late-stage candidates are co-developed and commercialized in Japan. | aabp.co.jp | Chiyoda, Japan | 2013 | Jan 2020 | •••• | |
Information on psoriasis medicine is provided via a dedicated website. | otezla.com | Thousand Oaks, United States | 2013 | Aug 2019 | $13.4B | |
Drug treatments for oncology and chronic inflammatory diseases are developed. | nuevolution.com | Copenhagen, Denmark | 2001 | May 2019 | $168.29M | |
IL-15 monoclonal antibodies for celiac disease therapies are developed. | celimmune.com | Bethesda, United States | 2015 | Jun 2017 | •••• |
Complete acquisition details for Amgen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Amgen
14 dated milestones of Amgen across 46 years, from founding to its latest funding, stage changes and deals.
- Founded Amgen is founded.
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $175.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Celimmune.
- Acquisition Acquires Nuevolution.
- Acquisition Acquires Otezla.
- Acquisition Acquires Amgen Astellas BioPharma.
- Acquisition Acquires Five Prime Therapeutics.
- Acquisition Acquires Rodeo Therapeutics.
- Acquisition Acquires TeneoBio.
- Acquisition Acquires ChemoCentryx.
- Acquisition Acquires Horizon Therapeutics.
- Acquisition Acquires Dark Blue Therapeutics.
Competitors of Amgen
Amgen has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others |
Detailed competitors of Amgen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Amgen
The website of Amgen (amgen.com) receives about 495.4K visits a month and ranks #116,434 among all websites worldwide, #3,445 in Biotechnology and Pharmaceuticals.
- Monthly visits495.4K
▲ 21.4% vs previous month
- Unique visitors202.4K
per month
- Global rank#116,434
among all websites
- Category rank#3,445
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.7
- Average visit2 min 00 sec
- DevicesDesktop 61% · Mobile 39%
Websites whose visitors overlap most with Amgen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| novartis.com | 91% | 948.8K | #58,822 | View details | |
| merck.com | 78% | 656.8K | #78,842 | View details | |
careers.lilly.com | careers.lilly.com | 77% | #60,411 | – | |
jobs.takeda.com | jobs.takeda.com | 73% | #185,912 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Amgen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Amgen (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 | ||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | USD 65.18 B | 47,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amgen
Complete news archive for Amgen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amgen
Amgen was founded in 1980 and raised its 1st funding round 30 years after it was founded.
Amgen is headquartered in Thousand Oaks, United States. It is registered at Thousand Oaks, California, United States.
Robert Bradway is the CEO of Amgen, as recorded in our data.
Amgen has 28,000 employees.
The primary company behind Amgen, Amgen Technology Private Limited, reported revenue of ₹166 Cr for FY 2025, up 601% year on year.
Amgen was founded in 1980 in Thousand Oaks, United States, within the biotechnology sector. Pharmaceutical products are developed to address multiple diseases through advances in cellular and molecular biology. Human therapeutics are manufactured and marketed, with operations centered on hematology, oncology, and inflammation. In 2022, annual revenues of 26.32 billion were achieved, alongside a net profit of 6.55 billion.
Amgen's top competitors include Roivant Sciences, AbbVie and Gilead.
Amgen offers Biologic Medicines and Clinical Trials Services.
Yes, Amgen is publicly traded on NASDAQ under the ticker symbol AMGN.
Amgen has made 26 acquisitions, including Abgenix, Alantos Pharmaceuticals, and Amgen Astellas BioPharma.
Amgen has 1 investor. Key investors include European Union.
Amgen operates through Amgen Technology Private Limited.